Inclisiran, a siRNA that targets proprotein convertase subtilisin/kexin Type 9(PCSK9), shows significant promise as an effective therapy for lowering LDL cholesterol levels, particularly in patients with FH. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.